Navigation Links
Star Scientific Reports on Filing Patent Application for Zero-Nitrosamine Tobacco Curing Process, Product Development by Rock Creek Pharmaceuticals
Date:4/16/2009

PETERSBURG, Va., April 16 /PRNewswire-FirstCall/ -- Star Scientific (Nasdaq: STSI) and its wholly-owned subsidiary, Rock Creek Pharmaceuticals ("Rock Creek"), today reported on their continuing efforts to lessen the harm linked with tobacco use. Star Scientific, through its CEO Jonnie R. Williams, recently filed a new US Patent Application for a novel modification of its patented curing technology that results in the production of tobacco leaf that consistently contains levels of carcinogenic TSNAs (known as NNNs and NNKs) that are below detection even by the most sensitive measures. That patent application for zero-nitrosamine tobacco currently is pending before the US Patent and Trademark Office.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090317/STARSCIENTIFICLOGO )

Rock Creek is exploring processes for the extraction of alkaloids from zero-nitrosamine tobacco for the purpose of using those alkaloids in the development of a generic nicotine replacement therapy (NRT), as well as a potential non-nicotine nutraceutical product. The nutraceutical would supply a dietary supplement for adult smokers who seek to minimize nicotine craving using a non-nicotine product. These development efforts are based in part on earlier research cited as support for the patents Star Scientific previously obtained for the use of tobacco alkaloids in treating various neurological conditions, including depression.

Curtis Wright, IV, MD, MPH, Medical Director of Rock Creek, stated, "We have acquired a large body of knowledge about why people smoke, and why smokers have been so unsuccessful in multiple quit attempts. We believe an appropriate strategy involves both an over-the-counter product and a parallel dietary supplement that may be of value in minimizing nicotine cravings."

Rock Creek and Star Scientific recently have developed a prototype nutraceutical product. The prototype combines minor alkaloids of tobacco with other ingredients typical of botanical-based, dietary supplement products. Contracts for initial benchtop and animal toxicity testing have been entered into by Rock Creek. Additional toxicity testing is expected to begin in the next few months. If those testing results and consumer acceptance studies of this product are favorable, Rock Creek anticipates using the brand name CigRx(TM) when it begins its test marketing effort. During the intervening period Star Scientific will be exploring a joint venture with either a pharmaceutical company or a marketing and distribution partner in order to be in a position to achieve broad market penetration with the new nutraceutical product

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Star Scientific, Inc. and its consolidated subsidiaries (collectively, the "Company") has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and contingencies include, without limitation, the challenges inherent in new product development initiatives, the uncertainties inherent in the progress of scientific research, the Company's ability to raise additional capital in the future necessary to maintain its business, potential disputes concerning the Company's intellectual property, risks associated with litigation regarding such intellectual property, potential delays in obtaining any necessary government approvals of the Company's low-TSNA tobacco products, market acceptance of the Company's new smokeless tobacco products, competition from companies with greater resources than the Company, the Company's decision not to join the Master Settlement Agreement ("MSA"), the effect of state statutes adopted under the MSA, and the Company's dependence on key employees and on its strategic relationships with Brown & Williamson Tobacco Corporation in light of its combination with RJ Reynolds Tobacco Company, Inc. The impact of potential litigation, if initiated against or by individual states that have adopted the MSA, could be materially adverse to the Company.

Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that the expectations will be attained or that any deviation will not be material. See additional discussion under "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, as filed with the SEC on March 16, 2009, and other factors detailed from time to time in the Company's other filings with the SEC, available at www.sec.gov. All information in this release is as of March 16, 2009, and the Company undertakes no obligation to update or advise upon any such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

About Rock Creek Pharmaceuticals

Rock Creek Pharmaceuticals develops pharmaceutical products for treatment of addiction and other neurological disorders. The company supports third-party academic, educational and therapeutic advances in both these areas of research. Rock Creek has scientific and research offices in Gloucester, MA.

About Star Scientific

Star Scientific is a technology-oriented tobacco company with a toxin reduction mission. It is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins (principally tobacco specific nitrosamines, or TSNAs), through the utilization of the innovative StarCured(R) tobacco curing technology, and in sublicensing that technology to others. Star Scientific has a Corporate and Sales Office in Petersburg, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and manufacturing facilities in Chase City, VA.

See Star's website at: http://www.starscientific.com

    Contact:
    Sara Troy Machir
    Vice President, Communications & Investor Relations
    smachir@starscientific.com
    (301) 654-8300


'/>"/>
SOURCE Star Scientific, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Thomson Scientific Predicts Nobel Laureates
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. Thomson Scientific Announces BONDplus for Biological Researchers
5. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
6. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
7. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
8. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
9. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
10. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
11. Delta Dental Plans Association Forms National Scientific Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a ... smoothing and tightening the skin of the face to create more youthful features. ... with very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure ...
(Date:12/7/2016)... , ... December 07, 2016 , ... It is vital ... is with useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, ... 'need for speed' and the need to operate in a GLP (Good Laboratory Practice) ...
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles ... minutes later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised ... teen the hospital’s 30th heart transplant recipient. , “He was playing at home, when ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... ... 2016 , ... The Honolulu cosmetic and medical dermatology practice ... October 17, 2016, features comprehensive information regarding a wide range of dermatologic conditions, ... can discover the latest clinical dermatology treatments for medical skin concerns as well ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... PARK , Israel , December 7, ... announced today the signing of a memorandum of understanding with Korean ... synergy between the companies will assist in expediting Kadimastem,s entry into ... in innovative treatment for severe diseases in general and ALS and ... , , ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, ... three-dimensional biology company focused on delivering scientific and ... announced that Chairman and Chief Executive Officer ... VirtualInvestorConferences.com on Wednesday, December 14, 2016 at 1:00 ... who are not yet familiar with the Company, ...
(Date:12/7/2016)... 7, 2016 The global  ... value of USD 3.9 billion by 2024, based ... Inc. The growth of the market is attributed ... technological advancements by the market players. Demand for ... increasing donation, rising awareness about transfusion-transmitted diseases, and ...
Breaking Medicine Technology: